Newsletter | October 19, 2021

10.19.21 -- Developing And Advancing Multi-Chain Biotherapeutics

A Toolbox Approach To Multi-Chain Molecules

In recent years, the number of biotherapeutic molecules requiring more complex assemblies has greatly increased. Typically, these multi-chain molecules are no longer compatible with platform approaches and require a more agile approach to early developability and method development.

Early Developability And Analytical Toolbox For The Production Of Multi-Chain Biotherapeutics

To de-risk the production of bispecific molecules, Lonza has developed a toolbox approach that allows for screening of titer and product assembly at an early stage in your product’s life cycle.

Maximize Your Chances Of Success: Avoid And Mitigate Risk Of Failure When Developing Biotherapeutics

Learn how in silico and in vitro protein design and optimization tools can help you to identify and mitigate manufacturing, development, and immunogenicity risks to reduce attrition and to improve the quality and safety of your therapeutic proteins.

Successful Techniques For Progressing Biotherapeutic Candidates From Late Discovery To The Clinic

Many initially promising biotherapeutic candidates fail due to lack of efficacy or safety, but there are also candidates that fail due to stability, aggregation, and other issues related to cell line or process issues. Prepare for a successful transition to bring your drug candidate from discovery to the clinic.

CEO Perspectives - Individual Journeys To Advance Molecules
Video: A Successful Small Biotech-CDMO Relationship

Simon Westbrook had an idea for a complex fusion chimera protein he believed could interrupt the neurotrophin pathway and have a profound impact on chronic pain and joint degeneration in osteoarthritis patients. He formed Levicept to develop this idea, and being a true virtual company, he needed a CDMO.

Read the full case study
Video: A Small Biotech With Two Complex Bispecific Antibody Candidates

Surrozen is developing novel and complex bispecific antibodies that target activation of the WNT pathway to take advantage of its regenerative potential. Although the WNT pathway has been studied for decades, Surrozen is aiming to develop the first therapeutics that intervene in this pathway and only in diseased tissue.

Read the full case study